右美托咪定治疗中毒性疾病:系统评价与毒理学研究者联盟数据库回顾
本文系统评价了右美托咪定用于除酒精戒断外中毒性疾病的文献,并回顾了毒理学研究者联盟(ToxIC)数据库。共纳入98项研究,其中87项为病例报告或病例系列(99例独特病例),11项其他设计研究(138例),ToxIC注册库93例符合标准。常见适应症包括兴奋剂中毒、镇静剂戒断、5-羟色胺综合征、抗胆碱能中毒综合征、阿片戒断和大麻素中毒;右美托咪定通常持续输注,不良反应不常见。证据质量普遍较低,主要因病例报告占多数、数据缺失或报告不佳以及几乎普遍合用其他镇静剂。作者认为,右美托咪定可能对某些中毒性疾病有帮助,尤其是兴奋剂中毒和镇静剂戒断,但需进一步高质量研究。
要点
- 右美托咪定治疗兴奋剂中毒有相当好的证据(59例),可能有效。
- 右美托咪定治疗镇静剂戒断(22例)有多篇高质量病例报告提示有效,尤其是巴氯芬戒断。
- 抗胆碱能中毒(42例)证据质量低,且较少使用首选解毒剂毒扁豆碱。
- 阿片戒断(44例)证据质量低,唯一高质量试验涉及超快速阿片脱毒,现代实践已不适用。
- 总体证据质量低,病例报告为主,数据缺失常见,且几乎普遍合用其他镇静剂。
适用人群与场景
- 除酒精戒断外的中毒性疾病患者,包括兴奋剂中毒、镇静剂戒断、5-羟色胺综合征、抗胆碱能中毒、阿片戒断和大麻素中毒。
- 排除:综述和评论、仅报告酒精戒断的研究、报告在重症监护室治疗医源性镇静剂戒断的研究。
处置流程与药物剂量
- 右美托咪定通常通过持续输注给药;少数病例报告使用负荷剂量。
- 抗胆碱能中毒时首选解毒剂为毒扁豆碱,但原文中较少使用。
研究设计与关键结果
- 系统评价共纳入98项研究,其中87项为病例报告或病例系列,代表99例独特病例;11项其他设计研究包括138例接受右美托咪定治疗的中毒性疾病患者;ToxIC注册库93例符合纳入标准。
- 兴奋剂中毒:59例接受右美托咪定治疗,有相当好的证据表明右美托咪定有帮助。
- 镇静剂戒断:22例接受右美托咪定治疗,数篇高质量病例报告提示有效,尤其是巴氯芬戒断。
- 5-羟色胺综合征:26例接受右美托咪定治疗,证据质量较低,因临床细节缺失、可能过度诊断5-羟色胺综合征以及几乎普遍合用其他镇静剂。
- 抗胆碱能中毒:42例接受右美托咪定治疗,证据质量低,且较少使用首选解毒剂毒扁豆碱。
- 阿片戒断:44例接受右美托咪定治疗,证据质量低,因临床细节缺失和几乎普遍合用其他药物;唯一高质量试验报告右美托咪定用于超快速阿片脱毒,现代实践已不适用。
- 大麻素中毒:5例接受右美托咪定治疗,有限证据无法得出明确结论。
- 不良反应不常见。
证据类型、等级与局限
- 证据类型:系统评价和ToxIC数据库回顾。
- 证据质量普遍较低,因病例报告占多数、数据缺失或报告不佳以及几乎普遍合用其他镇静剂。
- 局限:病例报告占多数、数据缺失或报告不佳、几乎普遍合用其他镇静剂;5-羟色胺综合征证据因临床细节缺失、可能过度诊断和几乎普遍合用其他镇静剂而质量较低;抗胆碱能中毒证据因较少使用毒扁豆碱而受限;阿片戒断证据因临床细节缺失和几乎普遍合用其他药物而质量低,唯一高质量试验涉及现代实践已不适用的超快速阿片脱毒;大麻素中毒证据有限无法得出结论。
对床旁实践的改变
- 作者认为,右美托咪定可能对某些中毒性疾病有帮助,尤其是兴奋剂中毒和镇静剂戒断。
- 需进一步高质量研究来明确右美托咪定在中毒性疾病患者中的作用。
- 应区分右美托咪定作为通用镇静剂(可能随着重症监护中总体使用增加而增加)与作为中毒性疾病的特异性药物治疗。
指南或共识出处
- 毒理学研究者联盟(ToxIC)数据库
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Dexmedetomidine is an alpha-2 adrenoceptor agonist which is widely used for sedation. Dexmedetomidine does not suppress the respiratory drive and produces a state of cooperative sedation; it may be associated with beneficial outcomes in the general critical care population. The role of dexmedetomidine in the treatment of toxicologic conditions (excluding alcohol withdrawal) is unclear.
OBJECTIVES: To critically assess and summarize the literature regarding the use of dexmedetomidine in toxicologic conditions other than alcohol withdrawal.
METHODS: We performed a systematic review of the medical literature to identify all existing evidence regarding the use of dexmedetomidine for toxicologic conditions. We excluded reviews and commentary, studies reporting exclusively on alcohol withdrawal, and studies reporting the use of dexmedetomidine to treat iatrogenic sedative withdrawal in the intensive care unit. We also performed a review of the Toxicology Investigators Consortium (ToxIC) database for patients treated with dexmedetomidine.
RESULTS: We identified 98 studies meeting inclusion criteria; 87 of these were case reports or case series, representing 99 unique cases. Eleven articles with other designs were identified, which included 138 patients treated with dexmedetomidine for toxicologic conditions. Ninety-three cases from the ToxIC registry met inclusion criteria. Common indications for dexmedetomidine included stimulant intoxication, sedative withdrawal, serotonin syndrome, antimuscarinic toxidrome, opioid withdrawal, and cannabinoid intoxication. Dexmedetomidine was usually administered by continuous infusion; bolus administration was reported in a minority of cases. Adverse effects were uncommon. The quality of evidence was generally low, given the preponderance of case reports, the rate of missing or poorly reported data, and the near-universal co-administration of other sedatives.
TREATMENT OF STIMULANT POISONING: Fifty-nine patients with stimulant poisoning were treated with dexmedetomidine. There was reasonably good evidence that dexmedetomidine was helpful in the treatment of stimulant poisoning.
TREATMENT OF SEDATIVE WITHDRAWAL: Twenty-two patients with sedative withdrawal were treated with dexmedetomidine. Several case reports of very high-quality suggested efficacy of dexmedetomidine for this indication, particularly for baclofen withdrawal.
TREATMENT OF SEROTONIN SYNDROME: Twenty-six patients with serotonin syndrome were treated with dexmedetomidine. This evidence was of lower quality due to missing clinical details, potential overdiagnosis of serotonin syndrome, and near-universal concomitant treatment with other sedatives.
TREATMENT OF ANTIMUSCARINIC POISONING: Forty-two patients with antimuscarinic poisoning were treated with dexmedetomidine. This evidence was of low quality and was limited by infrequent use of the preferred antidote, physostigmine.
TREATMENT OF OPIOID WITHDRAWAL: Forty-four patients with opioid withdrawal were treated with dexmedetomidine. This evidence was of low quality due to missing clinical details and near-universal concomitant treatment with other agents. The one high-quality trial reported the use of dexmedetomidine in ultra-rapid opioid detoxification, which is not indicated in modern practice.
TREATMENT OF CANNABINOID INTOXICATION: Five patients with cannabinoid intoxication were treated with dexmedetomidine. No definite conclusion can be drawn from the limited available evidence.
DISCUSSION: It is important to distinguish between the use of dexmedetomidine as a general sedative, which is likely to increase as the overall utilization of dexmedetomidine in critical care settings increases, and the use of dexmedetomidine as a specific pharmacologic treatment for a toxicologic condition. Well-established pharmacologic data from animal and human studies suggest dexmedetomidine counteracts stimulant-induced norepinephrine release. The mechanism by which dexmedetomidine treats sedative withdrawal is unclear. Some animal data show that dexmedetomidine may indirectly suppress serotonin release, which may suggest a role for dexmedetomidine in this condition.
CONCLUSIONS: There is a small and generally low-quality body of evidence which suggests that dexmedetomidine may be helpful in the treatment of certain toxicologic conditions, particularly stimulant intoxication and sedative withdrawal. Further high-quality research is needed to clarify the role of dexmedetomidine in patients with toxicologic conditions.
参考来源
- Baumgartner K, Doering And M, Mullins ME, et al. Dexmedetomidine in the treatment of toxicologic conditions: a systematic review and review of the toxicology investigators consortium database. Clin Toxicol (Phila). 2022. PMID: 36346349. doi:10.1080/15563650.2022.2138761
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。